Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meechai Tessalee

Interventional Cardiology Hinsdale, IL Medical Doctor

NPI 1841295193 CMS profile 672223

11 Salt Creek Ln, Ste 404, Hinsdale, IL 60521

Open in the dashboard

General payments

$2,557

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meechai Tessalee of Hinsdale, IL is reported in the CMS Open Payments database as having received $2,557 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $512 13
2024 General $467 13
2023 General $617 7
2022 General $288 13
2021 General $336 3
2019 General $336 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meechai Tessalee
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Meechai Tessalee were reported at $512. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Meechai Tessalee Interventional Cardiology median Middle half National median
2019 $336 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $336 $677 $233–$1,827 $132
2022 $288 $978 $333–$2,724 $149
2023 $617 $1,136 $382–$2,986 $160
2024 $467 $1,181 $395–$3,326 $164
2025 $512 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $611 18 payments
  2. Edwards Lifesciences Corporation $519 4 payments
  3. Shockwave Medical, Inc $352 3 payments
  4. Boston Scientific Corporation $213 5 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $187 3 payments
  6. Amgen Inc. $187 9 payments
  7. Impulse Dynamics (USA) Inc. $153 1 payment
  8. Philips Electronics North America Corporation $72 1 payment
  9. Janssen Pharmaceuticals, Inc $62 3 payments
  10. Novartis Pharmaceuticals Corporation $62 3 payments
  11. Other $139 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,387 54 payments
  2. Travel and Lodging $170 2 payments
Products named General payments · program years 2019–2025
  1. SYMPLICITY G3 $437 10 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $232 2 payments
  3. JARDIANCE $219 4 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $155 1 payment
  5. OPTIMIZER Cardiovascular Device $153 1 payment
  6. OPTIMIZER Cardiovascular Device $153 1 payment
  7. WATCHMAN Access System $152 3 payments
  8. ONYX FRONTIER $152 7 payments
  9. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $145 1 payment
  10. Repatha $136 6 payments
  11. Other $828 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,352

Median for Interventional Cardiology: 2,236

Drug cost

$492,636

Median for Interventional Cardiology: $380,412

Branded share of claims

23.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 192 $217,589
Xarelto Rivaroxaban Brand 99 $123,617
Entresto Sacubitril/Valsartan Brand 60 $39,592
Multaq Dronedarone Hcl Brand 26 $38,348
Repatha Sureclick Evolocumab Brand 28 $28,156
Metoprolol Succinate Generic 415 $6,212
Livalo Pitavastatin Calcium Brand 12 $4,434
Atorvastatin Calcium Generic 328 $4,247
Ezetimibe Generic 176 $3,512
Potassium Chloride Generic 109 $2,413

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$152,714

Medicare's payments for the services billed

Medicare patients

1,588

Average age 78

Services billed

3,401

864 women, 724 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 56%
Chronic kidney disease 42%
Diabetes 40%
Atrial fibrillation 40%
Heart failure 38%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $50
$50 99 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record